4D Molecular Therapeutics FDMT Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $72.49M+20.3% | $60.24M+24.1% | $48.56M-37.1% | $77.16M-42.2% | $133.53M-10.6% | ||
| $318.4M-7.0% | $342.41M+33.5% | $256.51M+18.7% | $216.07M+15.0% | $187.91M-31.8% | ||
| $405.36M-1.9% | $413.13M+32.3% | $312.38M+3.0% | $303.29M-8.8% | $332.57M-23.5% | ||
| $13.59M-8.6% | $14.87M-8.0% | $16.15M-7.7% | $17.51M-6.6% | $18.75M-4.0% | ||
| $512.91M-9.5% | $566.71M+33.7% | $423.98M-10.5% | $473.64M-8.2% | $515.73M-8.0% | ||
| $41.41M+34.1% | $30.87M+28.1% | $24.1M+19.5% | $20.16M+35.4% | $14.89M-0.4% | ||
| $360K0.0% | $360K0.0% | $360K-66.2% | $1.07M+23.1% | $866K+237% | ||
| $43.4M-1.3% | $43.99M+18.5% | $37.11M+7.0% | $34.68M+28.9% | $26.9M-7.7% | ||
| $61.07M0.0% | $61.05M+11.0% | $55M+4.3% | $52.75M+14.7% | $46.01M-7.6% | ||
| $5K-16.7% | $6K+20.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| -$785.06M-9.6% | -$716.3M+2.6% | -$735.7M-8.4% | -$678.83M-8.8% | -$624.17M-8.3% | ||
| $451.84M-10.6% | $505.66M+37.0% | $368.98M-12.3% | $420.89M-10.4% | $469.72M-8.0% | ||
| $512.91M-9.5% | $566.71M+33.7% | $423.98M-10.5% | $473.64M-8.2% | $515.73M-8.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are 4D Molecular Therapeutics's total assets?
- 4D Molecular Therapeutics (FDMT) holds $512.9M in total assets, down 0.5% year over year.
- How much debt does 4D Molecular Therapeutics have?
- 4D Molecular Therapeutics carries $20.5M in total debt against $451.8M of shareholders' equity, a debt-to-equity ratio of 0.05.
- How much cash does 4D Molecular Therapeutics have?
- 4D Molecular Therapeutics holds $72.5M in cash and equivalents.
- Can 4D Molecular Therapeutics cover its short-term obligations?
- Its current ratio is 9.34 — current assets exceed current liabilities.
- Where does 4D Molecular Therapeutics's balance sheet data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
